Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Astellas Pharma Inc
Astellas Pharma Inc
Massachusetts General Hospital
OBI Pharma, Inc
Thomas Jefferson University
Hunan Province Tumor Hospital
National Institutes of Health Clinical Center (CC)
Hunan Province Tumor Hospital
Hospital Israelita Albert Einstein
Fondazione per la Medicina Personalizzata
Syndax Pharmaceuticals
Eisai Inc.
ETOP IBCSG Partners Foundation
Fox Chase Cancer Center
National Cancer Center, Korea
National Cancer Center, Korea
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc
Intergroupe Francophone de Cancerologie Thoracique
Hoffmann-La Roche
Odense University Hospital
AVEO Pharmaceuticals, Inc.
Dutch Society of Physicians for Pulmonology and Tuberculosis
Albert Einstein College of Medicine
University of Texas Southwestern Medical Center
Albert Einstein College of Medicine
The First Affiliated Hospital of Guangzhou Medical University
Daiichi Sankyo
Dana-Farber Cancer Institute
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
Heat Biologics
M.D. Anderson Cancer Center
Montefiore Medical Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Swiss Cancer Institute
Swiss Cancer Institute
SCRI Development Innovations, LLC
Translational Oncology Research International
Weill Medical College of Cornell University
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins